Update on eosinophilic granulomatosis with polyangiitis

Area of Science:

• Rheumatology
• Immunology
• Pulmonology

Background:

• Eosinophilic granulomatosis with polyangiitis (EGPA), a rare ANCA-associated vasculitis, presents with eosinophilia and asthma.
• Research progress in EGPA has lagged due to its rarity and unique features.
• New international classification criteria are expected to accelerate EGPA research.

Purpose of the Study:

• To summarize current understanding and research directions in EGPA.
• To highlight advancements in EGPA classification and treatment.
• To identify unmet needs in EGPA management.

Main Methods:

• Review of recent literature on EGPA.
• Analysis of findings from international cohorts and genome-wide association studies.
• Evaluation of clinical trial data for emerging therapies.

Main Results:

• EGPA may comprise genetically distinct ANCA-positive and -negative subgroups.
• Mepolizumab demonstrated clinical benefits in a randomized controlled trial and is now approved for EGPA.
• Glomerulonephritis and heart failure frequencies differ between ANCA-positive and -negative EGPA patients.

Conclusions:

• EGPA classification is evolving, aiding future research.
• Mepolizumab offers a new treatment option, but relapse prevention and optimal drug use require further study.
• Understanding EGPA pathogenesis and distinct subgroups is crucial for personalized treatment.